Madrigal Pharmaceuticals Stock Performance
| MDGL Stock | USD 494.69 1.85 0.37% |
On a scale of 0 to 100, Madrigal Pharmaceuticals holds a performance score of 8. The company secures a Beta (Market Risk) of 0.56, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Madrigal Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Madrigal Pharmaceuticals is expected to be smaller as well. Please check Madrigal Pharmaceuticals' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Madrigal Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 99.9 M | |
| Total Cashflows From Investing Activities | -274.4 M | |
| Free Cash Flow | -457 M |
Madrigal Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 41,890 in Madrigal Pharmaceuticals on October 31, 2025 and sell it today you would earn a total of 7,579 from holding Madrigal Pharmaceuticals or generate 18.09% return on investment over 90 days. Madrigal Pharmaceuticals is currently generating 0.319% in daily expected returns and assumes 3.0893% risk (volatility on return distribution) over the 90 days horizon. In different words, 27% of stocks are less volatile than Madrigal, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Madrigal Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Madrigal Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 494.69 | 90 days | 494.69 | about 83.93 |
Based on a normal probability distribution, the odds of Madrigal Pharmaceuticals to move above the current price in 90 days from now is about 83.93 (This Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Madrigal Pharmaceuticals has a beta of 0.56. This indicates as returns on the market go up, Madrigal Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Madrigal Pharmaceuticals will be expected to be much smaller as well. Additionally Madrigal Pharmaceuticals has an alpha of 0.2802, implying that it can generate a 0.28 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Madrigal Pharmaceuticals Price Density |
| Price |
Predictive Modules for Madrigal Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Madrigal Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Madrigal Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Madrigal Pharmaceuticals is not an exception. The market had few large corrections towards the Madrigal Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Madrigal Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Madrigal Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.28 | |
β | Beta against Dow Jones | 0.56 | |
σ | Overall volatility | 46.67 | |
Ir | Information ratio | 0.08 |
Madrigal Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Madrigal Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Madrigal Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Madrigal Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 180.13 M. Net Loss for the year was (465.89 M) with profit before overhead, payroll, taxes, and interest of 705.49 M. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (455.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is DaVita Offering Value After A 36.9 percent One-Year Share Price Decline |
Madrigal Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Madrigal Stock often depends not only on the future outlook of the current and potential Madrigal Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Madrigal Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 21.3 M | |
| Cash And Short Term Investments | 926.3 M |
Madrigal Pharmaceuticals Fundamentals Growth
Madrigal Stock prices reflect investors' perceptions of the future prospects and financial health of Madrigal Pharmaceuticals, and Madrigal Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Madrigal Stock performance.
| Return On Equity | -0.41 | |||
| Return On Asset | -0.16 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.40) % | |||
| Current Valuation | 10.6 B | |||
| Shares Outstanding | 22.71 M | |||
| Price To Earning | (13.96) X | |||
| Price To Book | 18.16 X | |||
| Price To Sales | 15.34 X | |||
| Revenue | 180.13 M | |||
| EBITDA | (450.12 M) | |||
| Cash And Equivalents | 211.77 M | |||
| Cash Per Share | 12.38 X | |||
| Total Debt | 119.57 M | |||
| Debt To Equity | 0.59 % | |||
| Book Value Per Share | 27.56 X | |||
| Cash Flow From Operations | (455.57 M) | |||
| Earnings Per Share | (12.91) X | |||
| Total Asset | 1.04 B | |||
| Retained Earnings | (1.8 B) | |||
| Current Asset | 363.58 K | |||
| Current Liabilities | 49.28 M | |||
About Madrigal Pharmaceuticals Performance
By examining Madrigal Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Madrigal Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Madrigal Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. Madrigal Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 71 people.Things to note about Madrigal Pharmaceuticals performance evaluation
Checking the ongoing alerts about Madrigal Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Madrigal Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Madrigal Pharmaceuticals had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 180.13 M. Net Loss for the year was (465.89 M) with profit before overhead, payroll, taxes, and interest of 705.49 M. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (455.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Is DaVita Offering Value After A 36.9 percent One-Year Share Price Decline |
- Analyzing Madrigal Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Madrigal Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Madrigal Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Madrigal Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Madrigal Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Madrigal Pharmaceuticals' stock. These opinions can provide insight into Madrigal Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. Expected growth trajectory for Madrigal significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Madrigal Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Madrigal Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Madrigal Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Madrigal Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Madrigal Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Madrigal Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Madrigal Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.